Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $247.50 short call and a strike $252.50 long call offers a potential 30.21% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $247.50 by expiration. The full premium credit of $1.16 would be kept by the premium seller. The risk of $3.84 would be incurred if the stock rose above the $252.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Foghorn Therapeutics shares soar 26% premarket on news of cancer collaboration with Eli Lilly
Mon, 13 Dec 2021 11:14:18 +0000
Eli Lilly & Co. said Monday it has entered a strategic collaboration with Foghorn Therapeutics Inc. for novel oncology targets using Foghorn's proprietary gene traffic control platform, a move that sent Foghorn's shares up 26% in premarket trading. As part of the deal, Eli Lilly will pay $300 million upfront and make an equity investment in Foghorn of $80 million, priced at $20 a share. Foghorn shares closed Friday at $11.99. “Oncogenic mutations in BRG1 impact a large population of cancer patie
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform
Mon, 13 Dec 2021 11:00:00 +0000
– Establishes co-development and co-commercialization agreement on Foghorn’s selective BRM program and an additional undisclosed program – Collaboration includes three additional discovery programs – Foghorn to receive $300 million upfront and an equity investment by Lilly of $80 million at $20 per share INDIANAPOLIS and CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc.
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting
Sun, 12 Dec 2021 14:30:00 +0000
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). Pirtobrutinib is an investigational, highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor. These data are being presented in oral presentations at the 2021
Top 10 Stock Picks of John Overdeck and David Siegel’s Two Sigma Advisors
Sat, 11 Dec 2021 16:24:14 +0000
In this article, we discuss the top 10 stock picks of John Overdeck and David Siegel’s Two Sigma Advisors. If you want to skip our detailed analysis of these stocks, go directly to the Top 5 Stock Picks of John Overdeck and David Siegel’s Two Sigma Advisors. Two Sigma Advisors was co-founded by John Overdeck […]
2 Stocks to Buy if There Is a Market Crash
Sat, 11 Dec 2021 16:15:00 +0000
Here are two reasons why we could experience a market crash soon. First, stock valuations are at a 10-year high, as measured by the cyclically adjusted price-to-earnings (P/E) ratio. With that in mind, here are two excellent companies that could become even more attractive if there is a market downturn: Intuitive Surgical (NASDAQ: ISRG) and Eli Lilly (NYSE: LLY). Intuitive Surgical is one of the leaders in the robotic-assisted surgery (RAS) market — thanks to its da Vinci Surgical System which allows physicians to perform minimally invasive surgeries.
Also on Market Tamer…
Follow Us on Facebook